ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
enGene Therapeutics Inc.
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026
$1.58−0.09 (-5.39%)
Close on Oct 19, 2026
- Market cap
- $110.18M
- P/E (TTM)
- 0.7
- Dividend yield
- 0.00%
enGene Therapeutics statistics
Financials through Jul 31, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Market Cap | $105.89M | $166.30M |
| Enterprise Value | -$135.28M | $88.19M |
| PB Ratio | 0.46 | 2.03 |
| P/TBV Ratio | 0.46 | 2.29 |
Income (trailing twelve months)
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$136.65M | -$21.40M |
| Pretax Income | -$130.86M | -$14.34M |
| Net Income | -$130.36M | -$22.46M |
| EBITDA | -$135.96M | -$16.91M |
Returns
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -60.5% | -53.2% |
| Return on Assets (ROA) | -48.8% | -40.9% |
| Return on Invested Capital (ROIC) | -3862.3% | -32.4% |
| Return on Capital Employed (ROCE) | -52.3% | -38.1% |
Growth
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| EPS Growth (3Y CAGR) | -62.7% | -0.17% |
Balance sheet
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $266.32M | $61.43M |
| Total Debt | $25.16M | $118.52M |
| Net Cash (Debt) | $241.17M | $15.35M |
| Net Cash Per Share | $3.60 | $0.66 |
| Equity (Book Value) | $230.29M | $49.09M |
| Book Value Per Share | $3.44 | $1.37 |
| Tangible Book Value | $230.29M | $23.52M |
| Working Capital | $250.69M | $76.81M |
Financial position
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.21 | 3.34 |
| Quick Ratio | 9.79 | 2.44 |
| Debt / Equity | 0.11 | 0.52 |
| Interest Coverage | -44.51 | -6.26 |
Cash flow (trailing twelve months)
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$103.31M | -$12.35M |
| Capital Expenditures | -$688.00K | -$1.08M |
| Free Cash Flow | -$104.00M | -$20.22M |
| FCF Per Share | -$1.55 | -$0.42 |
Efficiency
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.59M | -$703.34K |
| Employee Count | 82 | 74 |
Dividends and yields
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -123.1% | -23.3% |
| FCF Yield | -98.2% | -8.72% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 67,016,300 | 58,127,000 |
| Shares Change (YoY) | 30.7% | 10.9% |
| Shares Change (QoQ) | 0.04% | 0.54% |
| Float | 57,399,000 | 49,136,700 |
| Shares Held by Insiders | 14.4% | 11.6% |
| Shares Held by Institutions | 61.1% | 59.4% |
Taxes
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$497.00K | $79.87K |
Scores
| Measure | enGene Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.68 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from enGene Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.